SHIRLEY VIA V GENTIVA HEALTH SERV INC
Annotate this Case
Download PDF
STATE OF MICHIGAN
COURT OF APPEALS
SHIRLEY VIA and JOHN VIA,
UNPUBLISHED
February 24, 2004
Plaintiffs-Appellants/CrossAppellees,
v
No. 244604
Macomb Circuit Court
LC No. 2002-000942-NO
GENTIVA HEALTH SERVICES, INC., f/k/a
OLSTEN HEALTH SERVICES,
Defendant-Appellee/Cross-
Appellant.
Before: Borrello, P.J., and White and Smolenski, JJ.
PER CURIAM.
Plaintiffs appeal as of right the circuit court’s grant of summary disposition to defendant
under MCR 2.116(C)(10), in this action alleging negligence arising from a contract1 between
defendant Gentiva and Berlex Laboratories, not a party to this suit. Defendant cross-appeals the
circuit court’s denial of its earlier motion for summary disposition, which it had brought on
different grounds. We affirm the circuit court’s grant of summary disposition to defendant.
Given that disposition, we need not address defendant’s cross-appeal.
I
Plaintiffs do not challenge the facts as stated in the circuit court’s final opinion and order:
Plaintiffs allege that defendant breached its duty to plaintiff Shirley Via by failing
to inform her of potential side effects concurrent with the administration of the
chemical Betaseron, failure to monitor plaintiff’s condition and failure to advise
plaintiff to seek appropriate medical care. Plaintiff was diagnosed with multiple
sclerosis in 1986. In 1998, plaintiff learned of a chemical designed to alleviate
some of the symptoms associated with the disease. Plaintiff began selfadministration of the chemical in January, 1999, and as a result, allegedly
1
Plaintiff John Via alleged loss of consortium.
-1-
developed skin necrosis at two sites on her body. Plaintiff filed a complaint
against defendant on February 26, 2002.
Plaintiffs’ complaint alleged that defendant Gentiva owed plaintiff Shirley Via (plaintiff)
a duty “to fully inform her of the potential consequences” of Betaseron injections; “to closely
monitor the reactions to the injections and to provide advice to the Plaintiff in such a manner as
to prevent the formation of necrotic tissue and the subsequent damage,” and “to provide a
product that was safe, suitable for its intended purpose and non-defective.” The record is clear
that plaintiff’s neurologist, Dr. Hidalgo, monitored plaintiff Shirley Via’s treatment and
prescribed Betaseron to her in the first instance. In connection with defendant’s motion for
summary disposition, plaintiffs argued that defendant Gentiva should have contacted Shirley Via
before she began injecting Betaseron on or around January 1, 1999. The record before the circuit
court showed that Dr. Hidalgo’s office authorized Gentiva to train plaintiff Shirley Via by a fax
dated January 14, 1999, which date fell after she began injecting Betaseron.
II
Plaintiffs first contend that the circuit court incorrectly determined that no further facts
could be discovered regarding the contract between defendant Gentiva and Berlex. Plaintiffs
contend that the circuit court granted defendant’s motion 1) before plaintiff’s treater, Dr. Cesar
Hidalgo, was deposed, and that Dr. Hidalgo maintained that he had conformed to the proper
procedures for contacting defendant (to authorize defendant to provide training to plaintiff); and
2) before defendant produced a copy of the contract between it and Berlex, which plaintiffs argue
they needed to determine defendant’s liability stemming from that contract.
This Court reviews de novo the circuit court’s grant of summary disposition. Smith v
Globe Life Ins, 460 Mich 446, 454-455; 597 NW2d 28 (1999). A motion under MCR
2.116(C)(10) tests the factual support for a claim. The circuit court must view the pleadings and
documentary evidence submitted in the light most favorable to the non-movant. Id. “Where the
burden of proof at trial on a dispositive issue rests on a nonmoving party, the nonmoving party. .
. must go beyond the pleadings to set forth specific facts showing that a genuine issue of material
fact exists.” Smith, supra quoting Quinto v Cross & Peters Co, 451 Mich 358, 362-363; 547
NW2d 314 (1996).
Plaintiffs’ argument is cursory,2 does not address the basis of the circuit court’s decision,
and does not properly represent the circuit court’s ruling. The circuit court’s opinion and order
granting summary disposition3 makes clear that it accepted as true the facts as alleged by
2
Plaintiffs’ appellate brief devotes less than two pages to this issue. Plaintiffs do not state
whether they brought to the circuit court’s attention that defendant had not produced the contract
while defendant’s motion was pending, nor do they state whether they filed a motion to compel
the contract’s production.
3
The circuit court granted defendant’s motion on proximate cause grounds:
(continued…)
-2-
(…continued)
Defendant first argues that plaintiff is unable to establish any causal relationship
between any action or inaction on defendant’s part and the injury allegedly
sustained by plaintiff. In response, plaintiff failed to squarely address this
argument; in essence, plaintiff’s response asserts defendant had a contractual duty
with Berlex to perform and provide training, they undertook that duty, and failed
in its performance by not properly contacting plaintiff.
At issue is whether plaintiff has created a triable issue of fact regarding
defendant’s liability in tort for plaintiff’s injuries in order to survive a (C)(10)
action [sic motion], particularly where the alleged breach of duty may be
characterized as a breach of contract between defendant and Berlex.
***
In the instant case, defendant allegedly agreed to provide plaintiff with services
under a contract defendant had with Berlex. Defendant allegedly failed to fully
perform according to the terms of its promise, and/or failed to properly perform,
i.e., failed to arrange training, failed to monitor plaintiff’s progress, and failed to
advise plaintiff to seek appropriate medical care when her alleged injuries were
recognized. . . .
[M]aterial documentation presented by the parties indicates that at the time
plaintiff began injecting herself with the chemical, she was well versed in its
potential side effects, was very clear on the injection procedure, and had had
numerous telephonic conversations with defendant clinic’s professional staff
regarding the preparation and procedures related to the proper usage of the
chemical. Plaintiff testified that she had received informative pamphlets, she read
them and thoroughly understood them: plaintiff additionally viewed on at least
one occasion, a video designed to aid patients in self-administration. Plaintiff
further testified that the first time she self-injected, she had talked to a nurse who
walked her through the process. Plaintiff stated that the first injection, in the thigh
area, went fine but for a resulting “little redness” at the site. Plaintiff testified that
she only injected herself in the thigh area twice, the area of the resulting alleged
necrosis, and thereafter chose spots on her body which contained more fat. . .
These areas did not develop necrosis. Plaintiff further testified that she was well
aware of the risks associated with the chemical, and that she knew injection site
reactions were common. The literature accompanying the product, which plaintiff
stated she had thoroughly read and understood, clearly stated in more than one
section “Serious adverse reactions associated with the use of Betaseron have been
reported including depression and injection site necrosis.”
Being well aware of this, the Court is advised that nevertheless, plaintiff
continued to self-inject even though she developed injuries to her thighs. Plaintiff
chose to continue despite developing necrosis, thus subjecting herself to potential
further injury. Plaintiff testified that the reasons she did not consult with her
(continued…)
-3-
plaintiff, including that defendant had agreed to provide plaintiff with services under a contract it
had with Berlex, i.e., had a duty to plaintiff Shirley Via. The basis of the court’s grant of
summary disposition to defendant was proximate cause. The extent of defendant’s liability under
the contract played no role in the proximate cause determination. Therefore, even if a copy of
the contract had been produced to plaintiffs, summary disposition would have been granted on
the basis of proximate cause.4
Plaintiffs fail to argue or explain how the circuit court’s proximate cause determination
would have differed had Dr. Hidalgo, plaintiff’s neurologist, been deposed before the circuit
court granted summary disposition. The factual statement in plaintiffs’ appellate brief states
regarding Dr. Hidalgo that defendant contacted him and obtained the proper orders for
proceeding with plaintiff Shirley Via’s training. The brief later states that Dr. Hidalgo
“maintained that he had conformed to the proper procedures for contact to Defendant.”
(…continued)
primary physician was because “Pathway” [M.S. Pathways was a patient support
program run by Berlex that instructed on Betaseron’s use] told her not to call her
doctor “every time I would call them.” This indicates that plaintiff had frequent
contact with some facility who continued to advise her while she remained on the
chemical. The record contains numerous detailed telephone logs indicating the
many contacts plaintiff had with defendant’s staff, in which advice for proper
injection was imparted to plaintiff; the logs additionally note that plaintiff
verbalized understanding of the directions.
The Court is satisfied that while reasonable factfinders could find defendant had
failed to inform plaintiff of the potential for the formation of necrotic tissue,
nevertheless as plaintiff was admittedly already well aware of the possible
adverse side effects this knowledge precludes liability. Further, the Court is also
satisfied that no question remains but that defendant did monitor plaintiff’s
condition so as to preclude the formation of the damages as indicated by the
numerous phone contacts and plaintiff’s own testimony. The potential for the
development of necrosis existed regardless of frequent or infrequent monitoring
as long as plaintiff was self-injecting. Plaintiff was also aware of the proper
procedure to minimize risk, and it appears she followed the procedure with or
without monitoring by defendant’s professionals. Finally, reasonable factfinders
could not disagree that despite defendant’s alleged advice not to contact her
physician, a reasonable person would have done so regardless in the event of a
serious injury. It is clear, however, that contacting her physician would not have
changed the situation as subsequent to the thigh injuries, plaintiff continued to
inject herself many times in other areas of her body with no resulting injury.
Therefore, the Court is convinced that no genuine issues of fact remain with
respect to any material facts, and defendant is entitled to judgment as a matter of
law.
4
Defendant’s motion was brought under MCR 2.116(C)(8) and (C)(10). The circuit court denied
the motion under MCR 2.116(C)(8), its opinion stating that “plaintiff has properly pleaded
sufficient facts to sustain a cause of action in tort for negligent performance of a contract.”
-4-
Defendant Gentiva contended below that it had no record of ever having received Dr. Hidalgo’s
order, and thus it was without authority to render any type of service to plaintiff Shirley Via.
Even had Dr. Hidalgo been deposed before the court granted defendant’s motion and even had he
testified that he gave defendant authority to train plaintiff Shirley Via before she began injecting
Betaseron, the court’s ruling on proximate cause would have been unaffected. As stated above,
the circuit court accepted as true that defendant had a duty to plaintiff under its contract with
Berlex at the time plaintiff self-injected Betaseron in her thighs. The issue whether defendant
received Dr. Hidalgo’s authorization to proceed with plaintiff’s training before plaintiff selfinjected the Betaseron in her thighs was of no consequence to the circuit court’s ruling.
Similarly, the question whether defendant had the duty in the first instance to contact
plaintiff (rather than the other way around) and failed to do so, played no role in the circuit
court’s determination to dismiss on proximate cause grounds. The court concluded based on
documentary evidence submitted in connection with defendant’s second motion that plaintiff
Shirley Via was well versed in both Betaseron’s potential side effects and the self-injection
procedure before she began self-injecting the chemical. Plaintiffs’ appellate brief does not argue
this determination was incorrect. We have reviewed the record and there is no evidence that
plaintiff Shirley Via used anything but proper technique in her self-injections. She testified at
deposition that she was never confused about self-injection and only called Pathways the first
time she injected herself because they told her to call so they could walk her through the process.
We find no error.
III
Plaintiffs next argue that the circuit court erred in granting summary disposition before
discovery was complete. Generally, summary disposition under MCR 2.116(C)(10) is premature
if granted before discovery on a disputed issue is complete. Colista v Thomas, 241 Mich App
529, 537; 616 NW2d 249 (2000). However, the nonmoving party must demonstrate by
independent evidence that a genuine issue of material fact exist in order to rely on this ground in
opposing summary disposition. Village of Diamondale v Grable, 240 Mich App 553, 557; 618
NW2d 23 (2000).
Plaintiffs’ entire argument in this regard is:
It is a well established standard in Michigan that summary disposition should not
be granted until discovery is completed. (See Standard of Review). In this
instance, even Plaintiff’s own treator’s testimony was not taken into consideration
prior to the Opinion and Order granting summary disposition to Defendant.
For that matter, Defendant’s own expert, Dr. Mikol, who was not deposed, stated
in his affidavit “use of proper injection techniques may help to lessen the chances
of a reaction.” (See Affidavit, Daniel D. Mikol June 27, 2002, Exhibit E)
Additionally, Defendant’s other expert, Dr. Elias [,] stated exactly the same.
(“Although uses of proper injection techniques may help to lessen the chances of
a reaction.” (See Affidavit, June 3, 2002, Exhibit F).
-5-
It is quite clear that Plaintiff was not afforded an opportunity to continue her
investigation of her claim and was prematurely cut off by the Trial Court.
Plaintiffs’ argument does not address the basis of the circuit court’s decision and fails for
the same reason their first argument fails—the court’s dismissal on grounds of proximate cause
would not have been altered had Dr. Hidalgo been deposed. Further, the fact that defendant’s
experts stated in affidavits that proper injection techniques may help lessen the chance of an
adverse physical reaction does nothing to assist plaintiffs on appeal given that plaintiff Shirley
Via was well aware of the possible adverse side effects of Betaseron before she began selfinjecting the chemical. As noted above, the record is devoid of evidence that Shirley Via used
anything but proper self-injection technique.
We affirm the circuit court’s grant of defendant’s second motion for summary
disposition. Given that disposition, we need not reach defendant’s cross-appeal.
/s/ Stephen L. Borrello
/s/ Helene N. White
/s/ Michael R. Smolenski
-6-
Some case metadata and case summaries were written with the help of AI, which can produce inaccuracies. You should read the full case before relying on it for legal research purposes.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.